Your session is about to expire
← Back to Search
RENEW for Scleroderma (RENEW Trial)
N/A
Waitlist Available
Led By Susan Murphy
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights
Summary
This trial is testing a program to see if it can help manage symptoms and the burden of scleroderma.
Eligible Conditions
- Scleroderma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Fatigue
Secondary outcome measures
Change in Depressive symptoms
Change in Pain Interference
Change in Resilience
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)Experimental Treatment1 Intervention
RENEW was created by researchers, doctors, and patients with scleroderma. It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
Group II: WaitlistActive Control1 Intervention
Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RENEW
2021
N/A
~310
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,817 Previous Clinical Trials
6,387,188 Total Patients Enrolled
9 Trials studying Scleroderma
575 Patients Enrolled for Scleroderma
Rheumatology Research FoundationOTHER
9 Previous Clinical Trials
7,197 Total Patients Enrolled
1 Trials studying Scleroderma
5,000 Patients Enrolled for Scleroderma
Susan MurphyPrincipal InvestigatorUniversity of Michigan
Share this study with friends
Copy Link
Messenger